ContraFect is a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA), including lysins and amurin peptides, as new medical modalities for the treatment of antibiotic-resistant infections. Co.'s main DLA product candidate, exebacase, is being developed in patients with chronic prosthetic joint infections of the knee due to S. aureus or coagulase-negative Staphylococci. Co.'s other product candidate, CF-370, is designed to target gram-negative bacteria, including P. aeruginosa, K. pneumoniae and A. baumannii, and is effective in vivo activity against these pathogens, even against multidrug-resistant and extensively drug-resistant strains.